Year |
Citation |
Score |
2023 |
Juric M, Rawat V, Amaradhi R, Zielonka J, Ganesh T. Novel NADPH Oxidase-2 Inhibitors as Potential Anti-Inflammatory and Neuroprotective Agents. Antioxidants (Basel, Switzerland). 12. PMID 37759963 DOI: 10.3390/antiox12091660 |
0.725 |
|
2023 |
Ganesh T. Targeting EP2 Receptor for Drug Discovery: Strengths, Weaknesses, Opportunities, and Threats (SWOT) Analysis. Journal of Medicinal Chemistry. 66: 9313-9324. PMID 37458373 DOI: 10.1021/acs.jmedchem.3c00655 |
0.461 |
|
2022 |
Rawat V, Eastman CL, Amaradhi R, Banik A, Fender JS, Dingledine RJ, D'Ambrosio R, Ganesh T. Temporal Expression of Neuroinflammatory and Oxidative Stress Markers and Prostaglandin E2 Receptor EP2 Antagonist Effect in a Rat Model of Epileptogenesis. Acs Pharmacology & Translational Science. 6: 128-138. PMID 36654746 DOI: 10.1021/acsptsci.2c00189 |
0.801 |
|
2022 |
Varvel NH, Amaradhi R, Espinosa-Garcia C, Duddy S, Franklin R, Banik A, Alemán-Ruiz C, Blackmar-Raynolds L, Wang W, Honore T, Ganesh T, Dingledine R. Preclinical development of an EP2 antagonist for post-seizure cognitive deficits. Neuropharmacology. 224: 109356. PMID 36460083 DOI: 10.1016/j.neuropharm.2022.109356 |
0.789 |
|
2022 |
Amaradhi R, Mohammed S, Banik A, Franklin R, Dingledine R, Ganesh T. Second-Generation Prostaglandin Receptor EP2 Antagonist, TG8-260, with High Potency, Selectivity, Oral Bioavailability, and Anti-Inflammatory Properties. Acs Pharmacology & Translational Science. 5: 118-133. PMID 35187419 DOI: 10.1021/acsptsci.1c00255 |
0.804 |
|
2022 |
Rawat V, Banik A, Amaradhi R, Rojas A, Taval S, Nagy T, Dingledine R, Ganesh T. Pharmacological antagonism of EP2 receptor does not modify basal cardiovascular and respiratory function, blood cell counts, and bone morphology in animal models. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 147: 112646. PMID 35091236 DOI: 10.1016/j.biopha.2022.112646 |
0.782 |
|
2021 |
Banik A, Amaradhi R, Lee D, Sau M, Wang W, Dingledine R, Ganesh T. Prostaglandin EP2 receptor antagonist ameliorates neuroinflammation in a two-hit mouse model of Alzheimer's disease. Journal of Neuroinflammation. 18: 273. PMID 34801055 DOI: 10.1186/s12974-021-02297-7 |
0.737 |
|
2021 |
Rojas A, Amaradhi R, Banik A, Jiang C, Abreu-Melon J, Wang S, Dingledine R, Ganesh T. A Novel Second-Generation EP2 Receptor Antagonist Reduces Neuroinflammation and Gliosis After Status Epilepticus in Rats. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 33410110 DOI: 10.1007/s13311-020-00969-5 |
0.825 |
|
2020 |
Jiang C, Caskurlu A, Ganesh T, Dingledine R. Inhibition of the prostaglandin EP2 receptor prevents long-term cognitive impairment in a model of systemic inflammation. Brain, Behavior, & Immunity - Health. 8: 100132. PMID 34589882 DOI: 10.1016/j.bbih.2020.100132 |
0.533 |
|
2020 |
Varvel NH, Espinosa-Garcia C, Hunter-Chang S, Chen D, Biegel A, Hsieh A, Blackmer-Raynolds L, Ganesh T, Dingledine R. Peripheral myeloid cell EP2 activation contributes to the deleterious consequences of status epilepticus. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 33293358 DOI: 10.1523/JNEUROSCI.2040-20.2020 |
0.819 |
|
2020 |
Jiang C, Amaradhi R, Ganesh T, Dingledine R. An Agonist Dependent Allosteric Antagonist of Prostaglandin EP2 Receptors. Acs Chemical Neuroscience. PMID 32324375 DOI: 10.1021/Acschemneuro.0C00078 |
0.669 |
|
2020 |
Amaradhi R, Banik A, Mohammed S, Patro V, Rojas A, Wang W, Motati DR, Dingledine R, Ganesh T. Potent, selective, water soluble, brain-permeable EP2 receptor antagonist for use in central nervous system disease models. Journal of Medicinal Chemistry. PMID 31904232 DOI: 10.1021/Acs.Jmedchem.9B01218 |
0.836 |
|
2020 |
Jiang C, Amaradhi R, Ganesh T, Dingledine R. A Noncompetitive and Selective Prostaglandin EP2 Antagonist with Anti‐inflammatory Property The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.00241 |
0.576 |
|
2019 |
Eastman CL, D'Ambrosio R, Ganesh T. Modulating neuroinflammation and oxidative stress to prevent epilepsy and improve outcomes after traumatic brain injury. Neuropharmacology. 107907. PMID 31837825 DOI: 10.1016/J.Neuropharm.2019.107907 |
0.383 |
|
2019 |
Rojas A, Banik A, Chen D, Flood K, Ganesh T, Dingledine R. A novel microglia cell line expressing the human EP2 receptor. Acs Chemical Neuroscience. PMID 31469538 DOI: 10.1021/Acschemneuro.9B00311 |
0.813 |
|
2019 |
Rojas A, Ganesh T, Wang W, Wang J, Dingledine R. A rat model of organophosphate-induced status epilepticus and the beneficial effects of EP2 receptor inhibition. Neurobiology of Disease. PMID 30818067 DOI: 10.1016/J.Nbd.2019.02.010 |
0.759 |
|
2018 |
Rojas A, Chen D, Ganesh T, Varvel NH, Dingledine R. The COX-2/prostanoid signaling cascades in seizure disorders. Expert Opinion On Therapeutic Targets. PMID 30484341 DOI: 10.1080/14728222.2019.1554056 |
0.831 |
|
2018 |
Ganesh T, Banik A, Dingledine R, Wang W, Amaradhi R. Peripherally restricted, highly potent, selective, aqueous-soluble EP2 antagonist with anti-inflammatory properties. Molecular Pharmaceutics. PMID 30398879 DOI: 10.1021/Acs.Molpharmaceut.8B00764 |
0.82 |
|
2018 |
Jiang J, Van TM, Ganesh T, Dingledine R. Discovery of 2-Piperidinyl Phenyl Benzamides and Trisubstituted Pyrimidines as Positive Allosteric Modulators of the Prostaglandin Receptor EP2. Acs Chemical Neuroscience. PMID 29292987 DOI: 10.1021/Acschemneuro.7B00486 |
0.79 |
|
2017 |
Kishore AH, Liang H, Kanchwala M, Xing C, Ganesh T, Akgul Y, Posner B, Ready JM, Markowitz SD, Word RA. Prostaglandin dehydrogenase is a target for successful induction of cervical ripening. Proceedings of the National Academy of Sciences of the United States of America. PMID 28716915 DOI: 10.1073/Pnas.1704945114 |
0.365 |
|
2017 |
Rojas A, Ganesh T, Walker A, Dingledine R. Ethylatropine bromide as a peripherally-restricted muscarinic antagonist. Acs Chemical Neuroscience. PMID 28044440 DOI: 10.1021/Acschemneuro.6B00334 |
0.72 |
|
2016 |
Rojas A, Ganesh T, Manji Z, O'neill T, Dingledine R. Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats. Neuropharmacology. PMID 27477533 DOI: 10.1016/J.Neuropharm.2016.07.028 |
0.726 |
|
2015 |
Li Y, Ganesh T, Diebold BA, Zhu Y, McCoy JW, Smith SM, Sun A, Lambeth JD. Thioxo-dihydroquinazolin-one Compounds as Novel Inhibitors of Myeloperoxidase. Acs Medicinal Chemistry Letters. 6: 1047-52. PMID 26487910 DOI: 10.1021/Acsmedchemlett.5B00287 |
0.371 |
|
2015 |
Ganesh T. Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2. Expert Opinion On Therapeutic Patents. 25: 837-44. PMID 25772215 DOI: 10.1517/13543776.2015.1025752 |
0.458 |
|
2015 |
Yuan H, Myers SJ, Wells G, Nicholson KL, Swanger SA, Lyuboslavsky P, Tahirovic YA, Menaldino DS, Ganesh T, Wilson LJ, Liotta DC, Snyder JP, Traynelis SF. Context-dependent GluN2B-selective inhibitors of NMDA receptor function are neuroprotective with minimal side effects. Neuron. 85: 1305-18. PMID 25728572 DOI: 10.1016/J.Neuron.2015.02.008 |
0.755 |
|
2015 |
Fu Y, Yang MS, Jiang J, Ganesh T, Joe E, Dingledine R. EP2 Receptor Signaling Regulates Microglia Death. Molecular Pharmacology. 88: 161-70. PMID 25715797 DOI: 10.1124/Mol.115.098202 |
0.78 |
|
2015 |
Rojas A, Ganesh T, Lelutiu N, Gueorguieva P, Dingledine R. Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus. Neuropharmacology. 93: 15-27. PMID 25656476 DOI: 10.1016/J.Neuropharm.2015.01.017 |
0.761 |
|
2015 |
Jiang J, Yang MS, Quan Y, Gueorguieva P, Ganesh T, Dingledine R. Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus. Neurobiology of Disease. 76: 126-36. PMID 25600211 DOI: 10.1016/J.Nbd.2014.12.032 |
0.817 |
|
2014 |
Ganesh T, Jiang J, Dingledine R. Development of second generation EP2 antagonists with high selectivity. European Journal of Medicinal Chemistry. 82: 521-35. PMID 24937185 DOI: 10.1016/J.Ejmech.2014.05.076 |
0.793 |
|
2014 |
Ganesh T, Jiang J, Yang MS, Dingledine R. Lead optimization studies of cinnamic amide EP2 antagonists. Journal of Medicinal Chemistry. 57: 4173-84. PMID 24773616 DOI: 10.1021/Jm5000672 |
0.811 |
|
2014 |
Rojas A, Jiang J, Ganesh T, Yang MS, Lelutiu N, Gueorguieva P, Dingledine R. Cyclooxygenase-2 in epilepsy. Epilepsia. 55: 17-25. PMID 24446952 DOI: 10.1111/Epi.12461 |
0.78 |
|
2014 |
Ganesh T. Prostanoid receptor EP2 as a therapeutic target Journal of Medicinal Chemistry. 57: 4454-4465. PMID 24279689 DOI: 10.1021/Jm401431X |
0.512 |
|
2013 |
Ganesh T, Jiang J, Shashidharamurthy R, Dingledine R. Discovery and characterization of carbamothioylacrylamides as EP2 selective antagonists. Acs Medicinal Chemistry Letters. 4: 616-621. PMID 23914286 DOI: 10.1021/Ml400112H |
0.783 |
|
2013 |
Jiang J, Quan Y, Ganesh T, Pouliot WA, Dudek FE, Dingledine R. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proceedings of the National Academy of Sciences of the United States of America. 110: 3591-6. PMID 23401547 DOI: 10.1073/Pnas.1218498110 |
0.831 |
|
2012 |
Smith SM, Min J, Ganesh T, Diebold B, Kawahara T, Zhu Y, McCoy J, Sun A, Snyder JP, Fu H, Du Y, Lewis I, Lambeth JD. Ebselen and congeners inhibit NADPH oxidase 2-dependent superoxide generation by interrupting the binding of regulatory subunits. Chemistry & Biology. 19: 752-63. PMID 22726689 DOI: 10.1016/J.Chembiol.2012.04.015 |
0.36 |
|
2012 |
Jiang J, Ganesh T, Du Y, Quan Y, Serrano G, Qui M, Speigel I, Rojas A, Lelutiu N, Dingledine R. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proceedings of the National Academy of Sciences of the United States of America. 109: 3149-54. PMID 22323596 DOI: 10.1073/Pnas.1120195109 |
0.836 |
|
2012 |
Zielonka J, Zielonka M, Ganesh T, Sun A, Cheng G, Michalski R, O'Brien W, Lambeth D, Kalyanaraman B. High-Throughput Screening (HTS) Assay for Identifying Potent and Selective Small-Molecule Inhibitors of NADPH Oxidases Free Radical Biology and Medicine. 53: S122. DOI: 10.1016/J.Freeradbiomed.2012.10.304 |
0.31 |
|
2011 |
Thaiparambil JT, Bender L, Ganesh T, Kline E, Patel P, Liu Y, Tighiouart M, Vertino PM, Harvey RD, Garcia A, Marcus AI. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation. International Journal of Cancer. Journal International Du Cancer. 129: 2744-55. PMID 21538350 DOI: 10.1002/Ijc.25938 |
0.308 |
|
2011 |
Thaiparambil JT, Bender L, Ganesh T, Kline E, Patel P, Liu Y, Tighiouart M, Vertino PM, Harvey RD, Garcia A, Marcus A. Abstract 822: Withaferin A inhibits breast cancer invasion and metastasis at subcytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation Cancer Research. 71: 822-822. DOI: 10.1158/1538-7445.Am2011-822 |
0.306 |
|
2011 |
Chapman-Rothe N, Shamsaei E, Cherblanc F, Ganesh T, Snyder JP, Fuchter MJ, Brown R. Abstract A162: Targeting chromatin: Small molecules reactivating H3K27me3 silenced genes. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A162 |
0.318 |
|
2011 |
Zielonka J, Zielonka M, Ganesh T, Sun A, Lambeth D, Kalyanaraman B. Inhibitors of NADPH Oxidase Decrease Peroxynitrite Formation in Activated Macrophages Free Radical Biology and Medicine. 51: S53. DOI: 10.1016/J.Freeradbiomed.2011.10.138 |
0.316 |
|
2010 |
Jiang J, Ganesh T, Du Y, Thepchatri P, Rojas A, Lewis I, Kurtkaya S, Li L, Qui M, Serrano G, Shaw R, Sun A, Dingledine R. Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proceedings of the National Academy of Sciences of the United States of America. 107: 2307-12. PMID 20080612 DOI: 10.1073/Pnas.0909310107 |
0.819 |
|
2009 |
Thepchatri P, Min J, Ganesh T, Du Y, Lewis I, Kurtkaya S, Prussia A, Li L, Sneed B, Plemper RK, Fu H, Liotta DC, Snyder JP, Dingledine R, Sun A. Cancer and virus leads by HTS, chemical design and SEA data mining. Current Topics in Medicinal Chemistry. 9: 1159-71. PMID 19807668 DOI: 10.2174/156802609789753581 |
0.512 |
|
2009 |
Thaiparambil J, Bender L, Kline E, Ganesh T, Snyder J, Liotta D, Marcus A. Vimentin: A Novel Chemopreventive Target for Breast Cancer Metastasis. Cancer Research. 69: 5063-5063. DOI: 10.1158/0008-5472.Sabcs-09-5063 |
0.306 |
|
2008 |
Ganesh T, Min J, Thepchatri P, Du Y, Li L, Lewis I, Wilson L, Fu H, Chiosis G, Dingledine R, Liotta D, Snyder JP, Sun A. Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling. Bioorganic & Medicinal Chemistry. 16: 6903-10. PMID 18571929 DOI: 10.1016/J.Bmc.2008.05.047 |
0.543 |
|
Show low-probability matches. |